Skip to main content
Fig. 4 | Cancer & Metabolism

Fig. 4

From: Metabolic convergence on lipogenesis in RAS, BCR-ABL, and MYC-driven lymphoid malignancies

Fig. 4

Inhibition of lipogenesis results in cell death. A TOFA treatment in either MYC, RAS, or BCR-ABL-dependent lymphoid results in significant increased cell death as detected by Annexin V and 7-AAD co-staining (quadrant 2) over t24 and 48 h timepoints (TOFA 5.5 μg/ml). Graphical representation of data to the right of flow plots. B NSG mice were intravenously injected with MYC-driven T-ALL cells derived from Eμ-tTA/Tet-O-MYC transgenic model and treated with TOFA for 4 days on, followed by 4 days off and then sacrificed. Cleaved caspase 3 is significantly more prevalent in splenic tissue from TOFA-treated mice when compared to control. C Spleens from mice that did not receive T-ALL cell injections but were treated with TOFA showed slightly less CC3 signal compared to vehicle control, suggesting that TOFA is only induced apoptosis in T-ALL cells in vivo. D Spleens were harvested from the wild-type FVB/N mice (transgenic background), RBC were lysed, and splenocytes were activated with ConA, followed by indicated treatments. TOFA treatment did not significantly impair the activated splenocyte population compare to the ConA alone control. Comparison to ConA control utilized an unpaired t-test **P 0.01

Back to article page